Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: von Emster leaving venBio for Abingworth

    Longtime biotech portfolio manager and VC Kurt von Emster has departed venBio, which he co-founded in 2009, and will join Abingworth as a partner in January.Abingworth said von Emster will work out of the London firm's …

    Published on 12/5/2014
  • FINANCIAL NEWS: BTG raises L150M, acquires PneumRx

    BTG plc (LSE:BTG) raised L150 million ($234.8 million) through the sale of 18.9 million shares at 795p in a placing underwritten by Deutsche Bank and JPMorgan. Invesco Asset Management purchased 3.3 million shares worth…

    Published on 12/4/2014
  • FINANCIAL NEWS: Evgen to list on AIM

    Evgen Pharma plc (Liverpool, U.K.) plans to raise up to L20 million ($31.3 million) in an IPO on the London Stock Exchange's AIM. The company expects shares to begin trading in mid-December. Westhouse Securities is the …

    Published on 12/4/2014
  • FINANCIAL NEWS: HBM joins Allena syndicate in $25M series B

    Allena Pharmaceuticals Inc. (Newton, Mass.) raised $25 million in a series B financing led by HBM Partners. Existing investors Frazier Healthcare; Third Rock Ventures; Bessemer Venture Partners; and new investor …

    Published on 12/4/2014
  • FINANCIAL NEWS: New Leaf closes $200M growth equity fund

    New Leaf Venture Partners closed a $200 million growth equity fund that will focus solely on investments in later-stage public biopharma companies. The firm's Philippe Chambon told BioCentury that New Leaf Growth Fund I…

    Published on 12/4/2014
  • FINANCIAL NEWS: Histogenics raises $65M in IPO

    Histogenics Corp. (NASDAQ:HSGX) rose $0.75 to $11.75 in its first day of trading after raising $65 million in an IPO on NASDAQ through the sale of 5.9 million shares at $11. The price valued Histogenics at $140.3 …

    Published on 12/3/2014
  • FINANCIAL NEWS: Naurex raises $80M in series C

    Neurology play Naurex Inc. (Evanston, Ill.) raised $80 million in an untranched series C round with new investors Cowen; EcoR1 Capital; Goudy Park Capital; Portola Capital; and Sabby Capital. Existing investors Adams …

    Published on 12/3/2014
  • FINANCIAL NEWS: Xeltis raises EUR 27M in series B

    Regenerative medicine play Xeltis AG (Zurich, Switzerland) raised EUR 27 million ($33.6 million) in a series B round led by new investors Life Sciences Partners and Kurma Partners. New investor VI Partners and …

    Published on 12/3/2014
  • FINANCIAL NEWS: Apellis raises $33M in series C

    Autoimmune disease play Apellis Pharmaceuticals Inc. (Crestwood, Ky.) closed a $33 million series C round led by existing investor Morningside Ventures and new investor AJU IB Investment Co. Ltd. Epidarex Capital, …

    Published on 12/2/2014
  • FINANCIAL NEWS: Canbridge raises $10M in series A

    Canbridge Life Sciences Ltd. (Beijing, China) raised $10 million in a series A round from Qiming Venture Partners and TF Capital. Canbridge in-licenses compounds from small biotechs in the U.S. and Europe to develop in …

    Published on 12/2/2014
  • FINANCIAL NEWS: Flexion proposes follow-on after FDA hold lifted

    Flexion Therapeutics Inc. (NASDAQ:FLXN) proposed to raise up to $69 million in a follow-on underwritten by BMO and RBC. The news came after Flexion announced postmarket Monday that FDA lifted a clinical hold on FX006 to…

    Published on 12/2/2014
  • FINANCIAL NEWS: Gene therapy play Audentes raises $42.5M

    Audentes Therapeutics Inc. (San Francisco, Calif.) raised $42.5 million in a series B round led by Deerfield Management. New investors Sofinnova Ventures and Venrock and existing investors OrbiMed, 5AM Ventures and …

    Published on 12/2/2014
  • FINANCIAL NEWS: Microbiome company Seres raises $48M

    Seres Health Inc. (Cambridge, Mass.) raised $48 million in a series C round with undisclosed public investors. Neither Seres nor founding investor Flagship Ventures would tell BioCentury who any of the investors in the …

    Published on 12/2/2014
  • FINANCIAL NEWS: PMV raises $30M series A

    PMV Pharmaceuticals Inc. (Redwood City, Calif.) raised $30 million in a series A round led by OrbiMed. Osage University Partners and founding investor InterWest Partners also participated. Peter Thompson, a private …

    Published on 12/2/2014
  • FINANCIAL NEWS: Ascendis raises $60M series D

    Prodrug technology developer Ascendis Pharma A/S (Copenhagen, Denmark) raised $60 million in a series D round led by Sofinnova Ventures; OrbiMed; and Vivo Capital. Janus Capital; Venrock; RA Capital; Rock Springs …

    Published on 12/1/2014
  • FINANCIAL NEWS: MDx play Curetis adds to B round

    Molecular diagnostics company Curetis AG (Holzgerlingen, Germany) raised EUR 14.5 million ($18 million) in an extension of its series B round. New investors Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) and LSP Health Economics …

    Published on 12/1/2014
  • FINANCIAL NEWS: Genomics Ltd. raises L10.3 million

    Sequencing analytics play and University of Oxford spin-out Genomics Ltd. (Oxford, U.K.) raised L10.3 million ($16.1 million) in its "first significant" round of funding, according to CEO John Colenutt. New investors …

    Published on 11/26/2014
  • FINANCIAL NEWS: Kite proposes $138M follow-on

    Kite Pharma Inc. (NASDAQ:KITE) said it plans to raise up to $138 million in a follow-on underwritten by Jefferies; Credit Suisse; Cowen; and Stifel. Kite raised $146.6 million through the sale of 8.6 million shares at $…

    Published on 11/26/2014
  • FINANCIAL NEWS: S1 Biopharma amends IPO

    S1 Biopharma Inc. (New York, N.Y.) amended its IPO on NASDAQ and plans to sell 1.75 million units at $12-$14. At $13, the company would raise $22.8 million and be valued at $105.7 million. Each unit comprises one share …

    Published on 11/26/2014
  • FINANCIAL NEWS: Eleven raises $20M in private placement

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO) raised $20 million through the sale of 1.7 million shares at $11.47 in a private placement with undisclosed investors. The company also issued three-year warrants to purchase …

    Published on 11/25/2014
  • FINANCIAL NEWS: Medgenics raises $21M in follow-on

    Medgenics Inc. (NYSE-M:MDGN) raised $21 million through the sale of 5.1 million shares at $4.10 in a follow-on underwritten by Piper Jaffray and JMP Securities.Medgenics' lead compound, TARGTEPO (MDGN-201), is in Phase …

    Published on 11/25/2014
  • FINANCIAL NEWS: Promethera raises EUR 20.3M in series C

    Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) raised EUR 20.3 million ($25.2 million) in a series C round led by existing investor Vesalius BioCapital. New investors included Germany's …

    Published on 11/25/2014
  • FINANCIAL NEWS: Ampio's Vyrix withdraws IPO

    The Vyrix Pharmaceutical Inc. subsidiary of Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) withdrew its proposed IPO on NYSE MKT, citing market conditions. In April, Vyrix filed to raise up to $28.8 million. Aegis Capital and…

    Published on 11/24/2014
  • FINANCIAL NEWS: Invus adds $150M to Lexicon investment

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) raised $150 million from an affiliate of Invus by selling shares in a private placement at $1.005 per share. The deal was disclosed in an SEC filing that also described the …

    Published on 11/24/2014
  • FINANCIAL NEWS: OnCore moving fast toward IPO

    In the wake of two deals to acquire HBV assets, OnCore Biopharma Inc. (Doylestown, Pa.) on Monday said it had submitted draft registration materials to SEC for a proposed IPO.OnCore was founded in 2012 by former …

    Published on 11/24/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993